Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The Andrews Research & Education Foundation is teaming up with Vector Science and Therapeutics to conduct the first well-controlled clinical studies on peptides in sports and regenerative medicine. The goal: cut through social media hype, establish evidence-based protocols, and ensure peptides are prescribed by physicians — not sourced from the internet.
Peptides have been buzzing on social media and in locker rooms, but rigorous clinical evidence has been largely absent — until now. The Andrews Research & Education Foundation and Vector Science and Therapeutics have announced a collaboration to conduct the first double-blinded, well-controlled studies on pharma-grade peptides in sports and regenerative medicine. The partnership aims to fill a critical research void and counter the spread of misinformation.
Initial research will focus on three key areas: accelerating soft tissue repair after activity or injury, stimulating muscle regeneration in aging athletes, and reducing the impact of degenerative osteoarthritis. Alongside the research, physician education programs will be developed to establish best practices and evidence-based protocols — including training for sports medicine fellows through the Foundation's existing educational platforms.
Key Takeaways:
Why it matters: As peptide use surges in sports and wellness communities, the lack of clinical evidence creates significant risks for patients. This collaboration could lay the scientific groundwork needed to legitimize — or debunk — peptide therapies and bring them safely into mainstream medical practice.